Skip to main content

Table 7 A comparison of BCMA-targeted treatment modalities in RRMM

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

  CAR-T/NK BITEs ADC
Logistics Manufacturing time bridging therapy required
Hospital infrastructure
Off the shelf Off the shelf
Setting Inpatient Inpatient- > outpatient Outpatient
Treatment One time treatment Mostly weekly dosing
Until PD
Q3w dosing
Until PD
Clinical benefit ORR 80%
Promising PFS and MRD data
ORR 60–80%
PFS data N/A
ORR 30%
Modest PFS with single agent
Adverse effects CRS 70–90%
(Grade >  = 3: 5–10%)
Neurotoxicity
Lymphodepletion
CRS 35–80%
(> = Grade3: 5–10%)
Neurotoxicity
Keratopathy
(> = Grade3: 20–25%)
Thrombocytopenia
Host T cell dependency Yes except in universal CAR-T/NK Yes No
  1. RRMM, refractory relapsed multiple myeloma; ORR, overall response rate; PFS, progression-free survival; MRD, minimal residual disease; CRS, cytokine release syndrome; q3w, every 3 weeks